Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 23

1.

Oestrogens Downregulate Tissue Factor Pathway Inhibitor through Oestrogen Response Elements in the 5'-Flanking Region.

Ali HO, Stavik B, Myklebust CF, Andersen E, Dahm AE, Iversen N, Sandset PM, Skretting G.

PLoS One. 2016 Mar 21;11(3):e0152114. doi: 10.1371/journal.pone.0152114. eCollection 2016.

2.

The chemical chaperone sodium 4-phenylbutyrate improves the secretion of the protein CA267T mutant in CHO-K1 cells trough the GRASP55 pathway.

Chollet ME, Skarpen E, Iversen N, Sandset PM, Skretting G.

Cell Biosci. 2015 Oct 9;5:57. doi: 10.1186/s13578-015-0048-4. eCollection 2015.

3.

Women's values and preferences for thromboprophylaxis during pregnancy: a comparison of direct-choice and decision analysis using patient specific utilities.

Eckman MH, Alonso-Coello P, Guyatt GH, Ebrahim S, Tikkinen KA, Lopes LC, Neumann I, McDonald SD, Zhang Y, Zhou Q, Akl EA, Jacobsen AF, Santamaría A, Annichino-Bizzacchi JM, Bitar W, Sandset PM, Bates SM.

Thromb Res. 2015 Aug;136(2):341-7. doi: 10.1016/j.thromres.2015.05.020. Epub 2015 May 22.

4.

Tumor expression, plasma levels and genetic polymorphisms of the coagulation inhibitor TFPI are associated with clinicopathological parameters and survival in breast cancer, in contrast to the coagulation initiator TF.

Tinholt M, Vollan HK, Sahlberg KK, Jernström S, Kaveh F, Lingjærde OC, Kåresen R, Sauer T, Kristensen V, Børresen-Dale AL, Sandset PM, Iversen N.

Breast Cancer Res. 2015 Mar 26;17:44. doi: 10.1186/s13058-015-0548-5.

5.

Syndecan-3 and TFPI colocalize on the surface of endothelial-, smooth muscle-, and cancer cells.

Tinholt M, Stavik B, Louch W, Carlson CR, Sletten M, Ruf W, Skretting G, Sandset PM, Iversen N.

PLoS One. 2015 Jan 24;10(1):e0117404. doi: 10.1371/journal.pone.0117404. eCollection 2015.

6.

Systematic reviews of observational studies of risk of thrombosis and bleeding in urological surgery (ROTBUS): introduction and methodology.

Tikkinen KA, Agarwal A, Craigie S, Cartwright R, Gould MK, Haukka J, Naspro R, Novara G, Sandset PM, Siemieniuk RA, Violette PD, Guyatt GH.

Syst Rev. 2014 Dec 23;3:150. doi: 10.1186/2046-4053-3-150. Review.

7.

Increased coagulation activity and genetic polymorphisms in the F5, F10 and EPCR genes are associated with breast cancer: a case-control study.

Tinholt M, Viken MK, Dahm AE, Vollan HK, Sahlberg KK, Garred O, Børresen-Dale AL, Jacobsen AF, Kristensen V, Bukholm I, Kåresen R, Schlichting E, Skretting G, Lie BA, Sandset PM, Iversen N.

BMC Cancer. 2014 Nov 19;14:845. doi: 10.1186/1471-2407-14-845.

8.

Women's experiences in relation to stillbirth and risk factors for long-term post-traumatic stress symptoms: a retrospective study.

Gravensteen IK, Helgadóttir LB, Jacobsen EM, Rådestad I, Sandset PM, Ekeberg O.

BMJ Open. 2013 Oct 22;3(10):e003323. doi: 10.1136/bmjopen-2013-003323.

9.

Symptom burden and job absenteeism after treatment with additional catheter-directed thrombolysis for deep vein thrombosis.

Enden T, Kløw NE, Sandset PM.

Patient Relat Outcome Meas. 2013 Sep 16;4:55-9. doi: 10.2147/PROM.S47233. eCollection 2013.

10.

Health-related quality of life after catheter-directed thrombolysis for deep vein thrombosis: secondary outcomes of the randomised, non-blinded, parallel-group CaVenT study.

Enden T, Wik HS, Kvam AK, Haig Y, Kløw NE, Sandset PM.

BMJ Open. 2013 Aug 29;3(8):e002984. doi: 10.1136/bmjopen-2013-002984.

11.

Targeted use of heparin, heparinoids, or low-molecular-weight heparin to improve outcome after acute ischaemic stroke: an individual patient data meta-analysis of randomised controlled trials.

Whiteley WN, Adams HP Jr, Bath PM, Berge E, Sandset PM, Dennis M, Murray GD, Wong KS, Sandercock PA.

Lancet Neurol. 2013 Jun;12(6):539-45. doi: 10.1016/S1474-4422(13)70079-6. Epub 2013 May 2.

12.

Cost-effectiveness of additional catheter-directed thrombolysis for deep vein thrombosis.

Enden T, Resch S, White C, Wik HS, Kløw NE, Sandset PM.

J Thromb Haemost. 2013 Jun;11(6):1032-42. doi: 10.1111/jth.12184.

13.

TFPIα and TFPIβ are expressed at the surface of breast cancer cells and inhibit TF-FVIIa activity.

Stavik B, Tinholt M, Sletten M, Skretting G, Sandset PM, Iversen N.

J Hematol Oncol. 2013 Jan 15;6:5. doi: 10.1186/1756-8722-6-5.

14.

Long-term impact of pregnancy-related venous thrombosis on quality-of-life, general health and functioning: results of a cross-sectional, case-control study.

Wik HS, Jacobsen AF, Sandvik L, Sandset PM.

BMJ Open. 2012 Nov 8;2(6). pii: e002048. doi: 10.1136/bmjopen-2012-002048. Print 2012.

15.

TFPI alpha and beta regulate mRNAs and microRNAs involved in cancer biology and in the immune system in breast cancer cells.

Stavik B, Skretting G, Olstad OK, Sletten M, Dehli Vigeland M, Sandset PM, Iversen N.

PLoS One. 2012;7(10):e47184. doi: 10.1371/journal.pone.0047184. Epub 2012 Oct 5.

16.

Long-term impact of intrauterine fetal death on quality of life and depression: a case-control study.

Gravensteen IK, Helgadottir LB, Jacobsen EM, Sandset PM, Ekeberg Ø.

BMC Pregnancy Childbirth. 2012 Jun 7;12:43. doi: 10.1186/1471-2393-12-43.

17.

Tissue factor pathway inhibitor, activated protein C resistance, and risk of ischemic stroke due to postmenopausal hormone therapy.

Rossouw JE, Johnson KC, Pettinger M, Cushman M, Sandset PM, Kuller L, Rosendaal F, Rosing J, Wasserthal-Smoller S, Martin LW, Manson JE, Lakshminarayan K, Merino JG, Lynch J.

Stroke. 2012 Apr;43(4):952-7. doi: 10.1161/STROKEAHA.111.643072. Epub 2012 Feb 23.

18.

Protein C mutation (A267T) results in ER retention and unfolded protein response activation.

Tjeldhorn L, Iversen N, Sandvig K, Bergan J, Sandset PM, Skretting G.

PLoS One. 2011;6(8):e24009. doi: 10.1371/journal.pone.0024009. Epub 2011 Aug 25.

19.

Downregulation of TFPI in breast cancer cells induces tyrosine phosphorylation signaling and increases metastatic growth by stimulating cell motility.

Stavik B, Skretting G, Aasheim HC, Tinholt M, Zernichow L, Sletten M, Sandset PM, Iversen N.

BMC Cancer. 2011 Aug 17;11:357. doi: 10.1186/1471-2407-11-357.

20.

An exploratory trial of cyclooxygenase type 2 inhibitor in HIV-1 infection: downregulated immune activation and improved T cell-dependent vaccine responses.

Pettersen FO, Torheim EA, Dahm AE, Aaberge IS, Lind A, Holm M, Aandahl EM, Sandset PM, Taskén K, Kvale D.

J Virol. 2011 Jul;85(13):6557-66. doi: 10.1128/JVI.00073-11. Epub 2011 Apr 13.

Items per page

Supplemental Content

Loading ...
Write to the Help Desk